Blue Owl Capital-owned data center company Stack Infrastructure Inc. is seeking a loan of around A$3 billion ($2.1 billion), according to people familiar with the matter, as it accelerates development ...

Newsletter platform Substack has confirmed a data breach in an email to users. The company said that in October, an “unauthorized third party” accessed user data, including email addresses, phone ...

SoftBank plans to deploy “Infrinia AI Cloud OS” initially within its own GPU cloud services. Furthermore, the Infrinia Team aims to expand deployment to overseas data centers and cloud environments ...

Abstract: As an ordered extension of evidence theory, Random permutation set (RPS) theory has received increasing attention due to its advantage in dealing with order-structured uncertain information.

Many engineering teams still rely on architecture optimized for transactional apps, not for AI systems that mix structured and unstructured data and live event streams. This legacy architecture has ...

A Colorado-based company, Stack Infrastructure, plans to build a new data center in New Albany, Ohio. The new 300,000-square-foot facility will be built next to the company's existing data center.

The healthcare industry generates about 30% of the world’s data. However, historically this data has been locked in silos and healthcare organizations have failed to generate real-time operational and ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

The artificial intelligence (AI) era demands a fundamental rethinking of strategic infrastructure and international partnerships. Just as oil shaped the geopolitical landscape of the 20th century, ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...